Patient follow-up complete in SANUWAVE's dermaPACE Phase III IDE trial for diabetic foot ulcers

SANUWAVE Health, Inc. (OTCBB:SNWV) (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced the completion of patient follow-up in the Company's pivotal Phase III, Investigational Device Exemption (IDE) clinical trial with dermaPACE™ for the treatment of diabetic foot ulcers.

A total of 206 patients were enrolled in the trial, which was conducted at 22 sites in the U.S. and two sites in Western Europe. Data entry will be completed in the coming weeks, followed by a final data review and then locking of the database in the fourth quarter of 2010. After the database is locked, the Company will unblind the data, conduct statistical analyses, announce top-line results publicly and draft the clinical study report. This work will culminate in submission of the final Premarket Approval (PMA) module to the U.S. Food and Drug Administration (FDA) late in 2010 or early in 2011.

The dermaPACE™ is the Company's lead product candidate for the global wound care market. It incorporates the Company's PACE™ (Pulsed Acoustic Cellular Expression) technology platform, which delivers a proprietary form of extracorporeal shock wave therapy (ESWT) to treat a wide variety of chronic and acute soft tissue conditions. The U.S. diabetic foot ulcer market is estimated at approximately $2 billion annually.

Christopher M. Cashman, President and CEO of SANUWAVE, said, "Despite advances in diabetes management, diabetic foot ulcers continue to be the most common cause of hospitalization among diabetics, and diabetes remains the single largest contributing factor to limb loss. Estimates indicate people with diabetes have a 25% lifetime risk for developing a foot ulcer, with half of these ulcers becoming infected. Of these infected ulcers, 1 in 4 will lead to amputation. Early detection and appropriate treatment of diabetic foot ulcers may eliminate the vast majority of amputations. The dermaPACE™, with its novel biologic regenerative effects, holds promise to heal diabetic foot ulcers and increase limb preservation, thus improving quality of life for these patients and their families and significantly easing the economic burden on an overwhelmed healthcare system that cares for these patients."

Mr. Cashman continued, "194 million people globally have diabetes, including 27 million people in the U.S. In any given year in the U.S. there are 3 million diabetic foot ulcers. Diabetes is recognized as a growing and serious global healthcare problem. In the U.S. alone, 54 million people are pre-diabetic, and the occurrence of diabetes onset is on the rise in many countries. It is imperative that caregivers have access to new, validated advanced wound healing modalities that can improve outcomes for patients suffering with diabetic foot ulcers. The dermaPACE™, as demonstrated by our complete body of clinical work, promotes wound closure and provides treatment in a cost-effective and clinically efficient manner."

Modular PMA Process Set to Begin

In August 2010 the FDA accepted SANUWAVE's shell application for dermaPACE™ proposing a modular PMA submission plan containing three sections or "modules." A modular submission divides the PMA document into modules filed at different times that together form the complete application. This modular approach allows the FDA to review each module separately as soon as it is received, making it possible for manufacturers to receive timely feedback during the review process, and perhaps shortening the time to a final regulatory determination.

The Company will submit the first two modules containing the preclinical data, prior clinical testing and a quality manufacturing system review to the FDA in October 2010. The Company plans to submit the third and final module containing the PMA application, clinical trial data, proposed product labeling and summary of safety and effectiveness late in 2010 or early in 2011.

Mr. Cashman concluded, "Initiating the dermaPACE™ PMA submission is an important milestone for SANUWAVE, as it brings us one step closer to our goal of introducing dermaPACE™ to stimulate wound healing and closure. Our diligent efforts to achieve a Class III PMA approval for dermaPACE™, the most stringent approval level granted in the U.S., will allow SANUWAVE to establish clinical credibility, differentiate our technology and create a significant barrier to entry for potential competitors. These factors, along with our extensive patent portfolio, provide a high degree of market protection and should enhance shareholder value. We look forward to working with the FDA to facilitate the review of this novel regenerative technology."

Source:

 SANUWAVE Health, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
How cruise ship passengers should prepare for sickness or injury at sea